MYIA
ABVX

Mount Yale Investment Advisors’s Abivax ABVX Stock Holding History

Mount Yale Investment Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700K Sell
5,256
-474
-8% -$53.6K 0.01% 684
2026
Q1 		$638K Buy
+5,730
New +$678K 0.01% 638

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mount Yale Investment Advisors's ABVX Position: Q2 2026 in Review

Mount Yale Investment Advisors reduced its Abivax (ABVX) stake by 8.3% in Q2 2026, selling an estimated $53.6K and leaving 5,256 shares worth $700K. The position accounts for 0.01% of the portfolio, ranked #684.

Mount Yale Investment Advisors first reported a position in ABVX in Q1 2026 and has held it in 2 quarters since. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Mount Yale Investment Advisors held 5,256 shares of Abivax worth $700K as of Q2 2026.
  • Mount Yale Investment Advisors sold 474 Abivax shares in Q2 2026, an estimated $53.6K.
  • Abivax made up 0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #684 holding.
  • Mount Yale Investment Advisors first reported a position in Abivax in Q1 2026 and has held it in 2 quarters since.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.